This page has only limited features, please log in for full access.

Unclaimed
Abdullah Algaissi
Medical Research Center, Jazan University, Jazan 45142, Saudi Arabia

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 04 August 2021 in Vaccines
Reads 0
Downloads 0

The urgent need for effective, safe and equitably accessible vaccines to tackle the ongoing spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of immunogens of SARS-CoV-2. Because of its crucial role in mediating binding and entry to host cell and its proven safety profile, the subunit 1 (S1) of the spike protein represents an attractive immunogen for vaccine development. Here, we developed and assessed the immunogenicity of a DNA vaccine encoding the SARS-CoV-2 S1. Following in vitro confirmation and characterization, the humoral and cellular immune responses of our vaccine candidate (pVAX-S1) was evaluated in BALB/c mice using two different doses, 25 µg and 50 µg. Our data showed high levels of SARS-CoV-2 specific IgG and neutralizing antibodies in mice immunized with three doses of pVAX-S1. Analysis of the induced IgG subclasses showed a Th1-polarized immune response, as demonstrated by the significant elevation of spike-specific IgG2a and IgG2b, compared to IgG1. Furthermore, we found that the immunization of mice with three doses of 50 µg of pVAX-S1 could elicit significant memory CD4+ and CD8+ T cell responses. Taken together, our data indicate that pVAX-S1 is immunogenic and safe in mice and is worthy of further preclinical and clinical evaluation.

ACS Style

Khalid Alluhaybi; Rahaf Alharbi; Rowa Alhabbab; Najwa Aljehani; Sawsan Alamri; Mohammad Basabrain; Rehaf Alharbi; Wesam Abdulaal; Mohamed Alfaleh; Levi Tamming; Wanyue Zhang; Mazen Hassanain; Abdullah Algaissi; Adel Abuzenadah; Xuguang Li; Anwar Hashem. Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1. Vaccines 2021, 9, 852 .

AMA Style

Khalid Alluhaybi, Rahaf Alharbi, Rowa Alhabbab, Najwa Aljehani, Sawsan Alamri, Mohammad Basabrain, Rehaf Alharbi, Wesam Abdulaal, Mohamed Alfaleh, Levi Tamming, Wanyue Zhang, Mazen Hassanain, Abdullah Algaissi, Adel Abuzenadah, Xuguang Li, Anwar Hashem. Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1. Vaccines. 2021; 9 (8):852.

Chicago/Turabian Style

Khalid Alluhaybi; Rahaf Alharbi; Rowa Alhabbab; Najwa Aljehani; Sawsan Alamri; Mohammad Basabrain; Rehaf Alharbi; Wesam Abdulaal; Mohamed Alfaleh; Levi Tamming; Wanyue Zhang; Mazen Hassanain; Abdullah Algaissi; Adel Abuzenadah; Xuguang Li; Anwar Hashem. 2021. "Cellular and Humoral Immunogenicity of a Candidate DNA Vaccine Expressing SARS-CoV-2 Spike Subunit 1." Vaccines 9, no. 8: 852.

Journal article
Published: 20 July 2021 in Viruses
Reads 0
Downloads 0

Healthcare workers (HCWs) are at high risk for SARS-CoV-2 infection compared to the general population. Here, we aimed to evaluate and characterize the SARS-CoV-2 seropositivity rate in randomly collected samples among HCWs from the largest referral hospitals and quarantine sites during the peak of the COVID-19 epidemic in the city of Jeddah, the second largest city in Saudi Arabia, using a cross-sectional analytic study design. Out of 693 participants recruited from 29 June to 10 August 2020, 223 (32.2%, 95% CI: 28.8–35.8) were found to be confirmed seropositive for SARS-CoV-2 antibodies, and among those 197 (88.3%) had never been diagnosed with COVID-19. Seropositivity was not significantly associated with participants reporting COVID-19 compatible symptoms as most seropositive HCW participants 140 (62.8%) were asymptomatic. The large proportion of asymptomatic SARS-CoV-2 cases detected in our study demands periodic testing as a general hospital policy.

ACS Style

Rowa Alhabbab; Ahdab Alsaieedi; Abdullah Algaissi; Sara Almahboub; Rajaa Al-Raddadi; Omaima Shabouni; Rahaf Alhabbab; Abdulelah Alfaraj; Sawsan Alamri; Najwa Aljehani; Rwaa Abdulal; Mohamed Alfaleh; Turki Abujamel; Almohanad Alkayyal; Ahmad Mahmoud; Adel Abuzenadah; Anwar Hashem. Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia. Viruses 2021, 13, 1413 .

AMA Style

Rowa Alhabbab, Ahdab Alsaieedi, Abdullah Algaissi, Sara Almahboub, Rajaa Al-Raddadi, Omaima Shabouni, Rahaf Alhabbab, Abdulelah Alfaraj, Sawsan Alamri, Najwa Aljehani, Rwaa Abdulal, Mohamed Alfaleh, Turki Abujamel, Almohanad Alkayyal, Ahmad Mahmoud, Adel Abuzenadah, Anwar Hashem. Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia. Viruses. 2021; 13 (7):1413.

Chicago/Turabian Style

Rowa Alhabbab; Ahdab Alsaieedi; Abdullah Algaissi; Sara Almahboub; Rajaa Al-Raddadi; Omaima Shabouni; Rahaf Alhabbab; Abdulelah Alfaraj; Sawsan Alamri; Najwa Aljehani; Rwaa Abdulal; Mohamed Alfaleh; Turki Abujamel; Almohanad Alkayyal; Ahmad Mahmoud; Adel Abuzenadah; Anwar Hashem. 2021. "Seroprevalence of SARS-CoV-2 Binding and Neutralizing Antibodies in Healthcare Workers during the Epidemic Peak in Referral Hospitals and Quarantine Sites: Saudi Arabia." Viruses 13, no. 7: 1413.

Journal article
Published: 18 June 2021 in Vaccines
Reads 0
Downloads 0

Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term post-vaccination side effects. Methods: Cross-sectional, retrospective study using an online questionnaire was conducted among COVID-19 vaccines recipients in Saudi Arabia. General and demographic data were collected, and vaccine-associated side effects after receiving at least one dose of each vaccine were evaluated. Results: Our final sample consisted of 515 participants with a median age of 26 years. Most of the study participants were female (57%). Nearly 13% of the study subjects have reported previous infections with SARS-CoV-2. Oxford-AstraZeneca and Pfizer-BioNTech vaccines have been received by 75% and 25% of the study participants, respectively. Side effects associated with COVID-19 vaccines have been reported by 60% of the study subjects, and most of them reported fatigue (90%), pain at the site of the injections (85%). Conclusion: Side effects that are reported post Oxford-AstraZeneca and Pfizer-BioNTech vaccines among our study participants are not different from those that were reported in the clinical trials, indicating safe profiles for both vaccines. Further studies are needed to evaluate the effectiveness of the current vaccines in protection against SARS-CoV-2 reinfections.

ACS Style

Abdulaziz Alhazmi; Edrous Alamer; Dalia Daws; Mashael Hakami; Majid Darraj; Siddig Abdelwahab; Amani Maghfuri; Abdullah Algaissi. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines 2021, 9, 674 .

AMA Style

Abdulaziz Alhazmi, Edrous Alamer, Dalia Daws, Mashael Hakami, Majid Darraj, Siddig Abdelwahab, Amani Maghfuri, Abdullah Algaissi. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021; 9 (6):674.

Chicago/Turabian Style

Abdulaziz Alhazmi; Edrous Alamer; Dalia Daws; Mashael Hakami; Majid Darraj; Siddig Abdelwahab; Amani Maghfuri; Abdullah Algaissi. 2021. "Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia." Vaccines 9, no. 6: 674.

Brief report
Published: 19 December 2020 in Pathogens
Reads 0
Downloads 0

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. Although several rapid commercial serological assays have been developed, little is known about their performance and accuracy in detecting SARS-CoV-2-specific antibodies in COVID-19 patient samples. Here, we have evaluated the performance of seven commercially available rapid lateral flow immunoassays (LFIA) obtained from different manufacturers, and compared them to in-house developed and validated ELISA assays for the detection of SARS-CoV-2-specific IgM and IgG antibodies in RT-PCR-confirmed COVID-19 patients. While all evaluated LFIA assays showed high specificity, our data showed a significant variation in sensitivity of these assays, which ranged from 0% to 54% for samples collected early during infection (3–7 days post symptoms onset) and from 54% to 88% for samples collected at later time points during infection (8–27 days post symptoms onset). Therefore, we recommend prior evaluation and validation of these assays before being routinely used to detect IgM and IgG in COVID-19 patients. Moreover, our findings suggest the use of LFIA assays in combination with other standard methods, and not as an alternative.

ACS Style

Anwar M. Hashem; Rowa Y. Alhabbab; Abdullah Algaissi; Mohamed A. AlFaleh; Sharif Hala; Turki S. Abujamel; M-Zaki ElAssouli; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Almohanad A. Alkayyal; Ahmad Bakur Mahmoud; Naif A. M. Almontashiri; Arnab Pain. Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies. Pathogens 2020, 9, 1067 .

AMA Style

Anwar M. Hashem, Rowa Y. Alhabbab, Abdullah Algaissi, Mohamed A. AlFaleh, Sharif Hala, Turki S. Abujamel, M-Zaki ElAssouli, Afrah A. Al-Somali, Fadwa S. Alofi, Asim A. Khogeer, Almohanad A. Alkayyal, Ahmad Bakur Mahmoud, Naif A. M. Almontashiri, Arnab Pain. Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies. Pathogens. 2020; 9 (12):1067.

Chicago/Turabian Style

Anwar M. Hashem; Rowa Y. Alhabbab; Abdullah Algaissi; Mohamed A. AlFaleh; Sharif Hala; Turki S. Abujamel; M-Zaki ElAssouli; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Almohanad A. Alkayyal; Ahmad Bakur Mahmoud; Naif A. M. Almontashiri; Arnab Pain. 2020. "Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies." Pathogens 9, no. 12: 1067.

Journal article
Published: 04 December 2020 in Viruses
Reads 0
Downloads 0

The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Antigen-specific responses are of unquestionable value for clinical management of COVID-19 patients. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized COVID-19 patients with different disease presentations (i.e., mild, moderate or severe), need for intensive care units (ICU) admission or outcomes (i.e., survival vs death). We show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Interestingly, significantly higher levels of nAbs as well as anti-S1 and -N IgG and IgM antibodies were found in patients with more severe symptoms, patients requiring admission to ICU or those with fatal outcomes. More importantly, early after symptoms onset, we found that the levels of anti-N antibodies correlated strongly with disease severity. Collectively, these findings provide new insights into the kinetics of antibody responses in COVID-19 patients with different disease severity.

ACS Style

Anwar M. Hashem; Abdullah Algaissi; Sarah A. Almahboub; Mohamed A. Alfaleh; Turki S. Abujamel; Sawsan S. Alamri; Khalid A. Alluhaybi; Haya I. Hobani; Rahaf H. AlHarbi; Reem M. Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K. Alharbi; Rowa Y. Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Abdullah Bukhari; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Arnab Pain; Almohanad A. Alkayyal; Naif A. M. Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses 2020, 12, 1390 .

AMA Style

Anwar M. Hashem, Abdullah Algaissi, Sarah A. Almahboub, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Khalid A. Alluhaybi, Haya I. Hobani, Rahaf H. AlHarbi, Reem M. Alsulaiman, M-Zaki ElAssouli, Sharif Hala, Naif K. Alharbi, Rowa Y. Alhabbab, Ahdab A. AlSaieedi, Wesam H. Abdulaal, Abdullah Bukhari, Afrah A. Al-Somali, Fadwa S. Alofi, Asim A. Khogeer, Arnab Pain, Almohanad A. Alkayyal, Naif A. M. Almontashiri, Ahmad Bakur Mahmoud, Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses. 2020; 12 (12):1390.

Chicago/Turabian Style

Anwar M. Hashem; Abdullah Algaissi; Sarah A. Almahboub; Mohamed A. Alfaleh; Turki S. Abujamel; Sawsan S. Alamri; Khalid A. Alluhaybi; Haya I. Hobani; Rahaf H. AlHarbi; Reem M. Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K. Alharbi; Rowa Y. Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Abdullah Bukhari; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Arnab Pain; Almohanad A. Alkayyal; Naif A. M. Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. 2020. "Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients." Viruses 12, no. 12: 1390.

Other
Published: 23 September 2020
Reads 0
Downloads 0

The Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Immunological surrogate markers, in particular antigen-specific responses, are of unquestionable value for clinical management of patients with COVID-19. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized patients with RT-PCR confirmed COVID-19 infection. Our data show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Notably, anti-S and -N IgG, peaked 20-40 day after disease onset, and were still detectable for at least up to 70 days, with nAbs observed during the same time period. Moreover, nAbs titers were strongly correlated with IgG antibodies. Significantly higher levels of nAbs as well as anti-S1 and N IgG and IgM antibodies were found in patients with more severe clinical presentations, patients requiring admission to intensive care units (ICU) or those with fatal outcomes. Interestingly, lower levels of antibodies, particularly anti-N IgG and IgM in the first 15 days after symptoms onset, were found in survivors and those with mild clinical presentations. Collectively, these findings provide new insights into the characteristics and kinetics of antibody responses in COVID-19 patients with different disease severity.

ACS Style

Anwar M Hashem; Abdullah Algaissi; Sarah A Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Sawsan S Alamri; Khalid A Alluhaybi; Haya I Hobani; Rahaf H AlHarbi; Reem M Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K Alharbi; Rowa Y Alhabbab; Ahdab A AlSaieedi; Wesam H Abdulaal; Abdullah Bukhari; Afrah A Al-Somali; Fadwa S Alofi; Asim A Khogeer; Arnab Pain; Almohanad A Alkayyal; Naif Am Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. 2020, 1 .

AMA Style

Anwar M Hashem, Abdullah Algaissi, Sarah A Almahboub, Mohamed A Alfaleh, Turki S Abujamel, Sawsan S Alamri, Khalid A Alluhaybi, Haya I Hobani, Rahaf H AlHarbi, Reem M Alsulaiman, M-Zaki ElAssouli, Sharif Hala, Naif K Alharbi, Rowa Y Alhabbab, Ahdab A AlSaieedi, Wesam H Abdulaal, Abdullah Bukhari, Afrah A Al-Somali, Fadwa S Alofi, Asim A Khogeer, Arnab Pain, Almohanad A Alkayyal, Naif Am Almontashiri, Ahmad Bakur Mahmoud, Xuguang Li. Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. . 2020; ():1.

Chicago/Turabian Style

Anwar M Hashem; Abdullah Algaissi; Sarah A Almahboub; Mohamed A Alfaleh; Turki S Abujamel; Sawsan S Alamri; Khalid A Alluhaybi; Haya I Hobani; Rahaf H AlHarbi; Reem M Alsulaiman; M-Zaki ElAssouli; Sharif Hala; Naif K Alharbi; Rowa Y Alhabbab; Ahdab A AlSaieedi; Wesam H Abdulaal; Abdullah Bukhari; Afrah A Al-Somali; Fadwa S Alofi; Asim A Khogeer; Arnab Pain; Almohanad A Alkayyal; Naif Am Almontashiri; Ahmad Bakur Mahmoud; Xuguang Li. 2020. "Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients." , no. : 1.

Preprint
Published: 02 July 2020
Reads 0
Downloads 0

As the coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2, continues to spread rapidly around the world, there is a need for well validated serological assays that allow the detection of viral specific antibody responses in COVID-19 patients or recovered individuals. In this study, we established and used multiple indirect Enzyme Linked Immunosorbent Assay (ELISA)-based serological assays to study the antibody response in COVID-19 patients. In order to validate the assays we determined the cut off values, sensitivity and specificity of the assays using sera collected from pre-pandemic healthy controls, COVID-19 patients at different time points after disease-onset, and seropositive sera to other human coronaviruses. The developed SARS-CoV-2 S1 subunit of the spike glycoprotein and nucleocapsid (N)-based ELISAs not only showed high specificity and sensitivity but also did not show any cross-reactivity with other CoVs. We also show that all RT-PCR confirmed COVID-19 patients tested in our study developed both virus specific IgM and IgG antibodies as early as week one after disease onset. Our data also suggest that the inclusion of both S1 and N in serological testing would capture as many potential SARS-CoV-2 positive cases as possible than using any of them alone. This is specifically important for tracing contacts and cases and conducting large-scale epidemiological studies to understand the true extent of virus spread in populations.

ACS Style

Abdullah Algaissi; Mohamed A. AlFaleh; Sherif Hala; Turki S. Abujamel; Sawsan S. Alamri; Sarah A Almahboub; Khalid A. Alluhaybi; Haya I. Hobani; Reem M. Alsulaiman; Rahaf H. Alharbi; M-Zaki El-Assouli; Rowa Y Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Naif A.M. Almontashiri; Arnab Pain; Anwar M. Hashem. SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. 2020, 1 .

AMA Style

Abdullah Algaissi, Mohamed A. AlFaleh, Sherif Hala, Turki S. Abujamel, Sawsan S. Alamri, Sarah A Almahboub, Khalid A. Alluhaybi, Haya I. Hobani, Reem M. Alsulaiman, Rahaf H. Alharbi, M-Zaki El-Assouli, Rowa Y Alhabbab, Ahdab A. AlSaieedi, Wesam H. Abdulaal, Afrah A. Al-Somali, Fadwa S. Alofi, Asim A. Khogeer, Ahmad Bakur Mahmoud, Almohanad A Alkayyal, Naif A.M. Almontashiri, Arnab Pain, Anwar M. Hashem. SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. . 2020; ():1.

Chicago/Turabian Style

Abdullah Algaissi; Mohamed A. AlFaleh; Sherif Hala; Turki S. Abujamel; Sawsan S. Alamri; Sarah A Almahboub; Khalid A. Alluhaybi; Haya I. Hobani; Reem M. Alsulaiman; Rahaf H. Alharbi; M-Zaki El-Assouli; Rowa Y Alhabbab; Ahdab A. AlSaieedi; Wesam H. Abdulaal; Afrah A. Al-Somali; Fadwa S. Alofi; Asim A. Khogeer; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Naif A.M. Almontashiri; Arnab Pain; Anwar M. Hashem. 2020. "SARS-CoV-2 S1 and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients." , no. : 1.

Preprint
Published: 23 May 2020
Reads 0
Downloads 0

Emerging highly pathogenic human coronaviruses (CoVs) represent a serious ongoing threat to the public health worldwide. The spike (S) proteins of CoVs are surface glycoproteins that facilitate viral entry into host cells via attachment to their respective cellular receptors. The S protein is believed to be a major immunogenic component of CoVs and a target for neutralizing antibodies (nAbs) and most candidate vaccines. Development of a safe and convenient assay is thus urgently needed to determine the prevalence of CoVs nAbs in the population, to study immune response in infected individuals, and to aid in vaccines and viral entry inhibitors evaluation. While live virus-based neutralization assays are used as gold standard serological methods to detect and measure nAbs, handling of highly pathogenic live CoVs requires strict bio-containment conditions in biosafety level-3 laboratories. On the other hand, use of replication-incompetent pseudoviruses bearing CoVs S proteins could represent a safe and useful method to detect nAbs in serum samples under biosafety level-2 conditions. Here, we describe a detailed protocol of a safe and convenient assay to generate vesicular stomatitis virus (VSV)-based pseudoviruses to evaluate and measure nAbs against highly pathogenic CoVs. The protocol covers methods to produce VSV pseudovirus bearing the S protein of the Middle East respiratory syndrome-CoV (MERS-CoV) and the severe acute respiratory syndrome-CoV-2 (SARS-CoV-2), pseudovirus titration, and pseudovirus neutralizing assay. Such assay could be adapted by different laboratories and researchers working on highly pathogenic CoVs without the need to handle live viruses in biosafety level-3 environment.

ACS Style

Sarah A. Almahboub; Abdullah Algaissi; Mohamed A. AlFaleh; M-Zaki ElAssouli; Anwar M. Hashem. Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based Assay. 2020, 1 .

AMA Style

Sarah A. Almahboub, Abdullah Algaissi, Mohamed A. AlFaleh, M-Zaki ElAssouli, Anwar M. Hashem. Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based Assay. . 2020; ():1.

Chicago/Turabian Style

Sarah A. Almahboub; Abdullah Algaissi; Mohamed A. AlFaleh; M-Zaki ElAssouli; Anwar M. Hashem. 2020. "Evaluation of Neutralizing Antibodies against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus (Vsv) Pseudovirus-Based Assay." , no. : 1.

Review article
Published: 06 May 2020 in Travel Medicine and Infectious Disease
Reads 0
Downloads 0

The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.

ACS Style

Anwar M. Hashem; Badrah S. Alghamdi; Abdullah A. Algaissi; Fahad S. Alshehri; Abdullah Bukhari; Mohamed Alfaleh; Ziad A. Memish. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Medicine and Infectious Disease 2020, 35, 101735 -101735.

AMA Style

Anwar M. Hashem, Badrah S. Alghamdi, Abdullah A. Algaissi, Fahad S. Alshehri, Abdullah Bukhari, Mohamed Alfaleh, Ziad A. Memish. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Medicine and Infectious Disease. 2020; 35 ():101735-101735.

Chicago/Turabian Style

Anwar M. Hashem; Badrah S. Alghamdi; Abdullah A. Algaissi; Fahad S. Alshehri; Abdullah Bukhari; Mohamed Alfaleh; Ziad A. Memish. 2020. "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review." Travel Medicine and Infectious Disease 35, no. : 101735-101735.

Preprint
Published: 02 April 2020
Reads 0
Downloads 0

Nearly three months have passed since the emergence of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), which caused the rapidly spreading Coronavirus Disease 2019 (COVID-19) pandemic. To date, there have been more than 550,000 confirmed cases and more than 25,000 deaths globally caused by COVID-19. Chinese health authorities, where the virus emerged, have taken prompt strict public health measures to control and prevent the spread of the outbreak. In the kingdom of Saudi Arabia, unprecedented precautionary strict measures were applied to slow virus entry and to mitigate the risk of the outbreak. Here, we review the experience learned during the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) epidemic in Saudi Arabia, which has been in the country since 2012, and is expected to have helped the country to be well prepared for the current COVID-19 pandemic. We also discuss the country readiness, improvement in research and development, and the unprecedented rapid precautionary measures that have been taken by the Saudi government thus far.

ACS Style

Abdullah Algaissi; Naif Alharbi; Mazen Hassanain; Anwar Hashem. Preparedness and Response to COVID-19 in Saudi Arabia: Lessons Learned from MERS-CoV . 2020, 1 .

AMA Style

Abdullah Algaissi, Naif Alharbi, Mazen Hassanain, Anwar Hashem. Preparedness and Response to COVID-19 in Saudi Arabia: Lessons Learned from MERS-CoV . . 2020; ():1.

Chicago/Turabian Style

Abdullah Algaissi; Naif Alharbi; Mazen Hassanain; Anwar Hashem. 2020. "Preparedness and Response to COVID-19 in Saudi Arabia: Lessons Learned from MERS-CoV ." , no. : 1.